Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1506251
Sentiment: neutral
Topics: reporting, disclosure
Related Tickers: CTRS
TL;DR
CTRS filed a standard 8-K, no major news.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Nevada, has its principal executive offices in Cranford, NJ. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Citius Pharmaceuticals, Inc. It does not disclose new material events or financial performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new material events or risks.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Principal executive offices
- October 23, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Citius Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. was incorporated in Nevada.
Where are Citius Pharmaceuticals, Inc.'s principal executive offices located?
Citius Pharmaceuticals, Inc.'s principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number for Citius Pharmaceuticals, Inc. is 001-38174.
What is the IRS Employer Identification Number for Citius Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Citius Pharmaceuticals, Inc. is 27-3425913.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-23 17:12:30
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0262321-8k_citius.htm (8-K) — 23KB
- ea026232101ex99-1_citius.htm (EX-99.1) — 36KB
- ex99-1_001.jpg (GRAPHIC) — 2834KB
- ex99-1_002.jpg (GRAPHIC) — 2175KB
- ex99-1_003.jpg (GRAPHIC) — 900KB
- ex99-1_004.jpg (GRAPHIC) — 1258KB
- ex99-1_005.jpg (GRAPHIC) — 1177KB
- ex99-1_006.jpg (GRAPHIC) — 1306KB
- ex99-1_007.jpg (GRAPHIC) — 1815KB
- ex99-1_008.jpg (GRAPHIC) — 1701KB
- ex99-1_009.jpg (GRAPHIC) — 1280KB
- ex99-1_010.jpg (GRAPHIC) — 794KB
- ex99-1_011.jpg (GRAPHIC) — 1020KB
- ex99-1_012.jpg (GRAPHIC) — 1692KB
- ex99-1_013.jpg (GRAPHIC) — 1635KB
- ex99-1_014.jpg (GRAPHIC) — 1285KB
- ex99-1_015.jpg (GRAPHIC) — 512KB
- ex99-1_016.jpg (GRAPHIC) — 1243KB
- ex99-1_017.jpg (GRAPHIC) — 1791KB
- ex99-1_018.jpg (GRAPHIC) — 2002KB
- ex99-1_019.jpg (GRAPHIC) — 933KB
- ex99-1_020.jpg (GRAPHIC) — 1320KB
- ex99-1_021.jpg (GRAPHIC) — 1245KB
- ex99-1_022.jpg (GRAPHIC) — 475KB
- ex99-1_023.jpg (GRAPHIC) — 1160KB
- ex99-1_024.jpg (GRAPHIC) — 445KB
- ex99-1_025.jpg (GRAPHIC) — 807KB
- ex99-1_026.jpg (GRAPHIC) — 3636KB
- 0001213900-25-101741.txt ( ) — 50413KB
- ctxr-20251023.xsd (EX-101.SCH) — 3KB
- ctxr-20251023_lab.xml (EX-101.LAB) — 33KB
- ctxr-20251023_pre.xml (EX-101.PRE) — 22KB
- ea0262321-8k_citius_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 23, 2025, Citius Pharmaceuticals, Inc. posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit is filed herewith: Exhibit No. Description 99.1 Corporate Presentation of October 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: October 23, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2